AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 21.47 |
Market Cap | 1.53B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.78 |
PE Ratio (ttm) | -5.78 |
Forward PE | n/a |
Analyst | Buy |
Ask | 22.87 |
Volume | 1,041,577 |
Avg. Volume (20D) | 641,716 |
Open | 22.81 |
Previous Close | 22.63 |
Day's Range | 21.34 - 23.20 |
52-Week Range | 15.32 - 37.00 |
Beta | undefined |
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...
Analyst Forecast
According to 8 analyst ratings, the average rating for AKRO stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 110.53% from the latest price.